Back
AUK
Aumake Limited
๐ฆ๐บ ASX
๐๏ธ CONSUMER
๐ Overview
๐ Performance
๐ต Cost
๐ค Advanced
๐จโ๐ฉโ๐งโ๐ฆ Community
๐
-19.09%
Annual Growth
5 years average annual capital growth
๐ต
$ 500
Minimum Order
Due to regulatory requirements
๐
1
Pearlers Invested
Since January 2020
๐ Overview
Key information
๐ Fund Overview
AuMake Ltd. engages in the retail of Australian products to Chinese consumers through online platform and retail stores in Sydney. The firm is engaged in the sale of Australian and New Zealand products via social e-commerce marketplace platforms. The company is focused on a multi-brand, omni-channel retail business. Its services include e-commerce platform, marketing, live streaming, brand experience stores, customer service, warehousing and freight and logistics. The company offers an omnichannel solution for business merchants to Asian audiences. This includes eCommerce via its Website, mini-apps, live-streaming, and social media options to suit individual country preferences. Its marketing services include brand strategy development, omnichannel marketing campaign creation, live-streaming, content creation, and content management-social media schedules and uploading. Its Live streaming creates opportunities for business owners to connect with their customers from around the world, entertain them, create instant buying opportunities, and develop trusted brand connections.
๐ Performance
Price History
-98.54%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
๐๏ธ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out โ๐ต Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out โโฑ๏ธ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out โ๐ต Costs
๐ผ
N/A
Management Fee
Included in unit price, not charged by Pearler
๐ธ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐ธ Net fee calculator๐ค Advanced information
Technical Info
๐ฐ Price*
$0.00
*Price may be up to 24 hours old
๐ฉโ๐ฉโ๐ฆ Community Insights
How our community is investing
๐ Pearlers invested in AUK
1
๐ Total Capital Earnings
N/A
๐ Average investment frequency
N/A
๐ต Average investment amount
N/A
โฐ Last time a customer invested in AUK
N/A
AUK investor breakdown
๐ต Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
100%
Less than 50k
๐ถ Age of investors
18 - 25
26 - 34
35 - 90
100%
๐ Legal gender of investors
Female
Male
100%
Pearlers who invest in AUK also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
๐ Performance (5Yr p.a)
9.16%
๐ Share price
$109.50 AUD
๐ฆ๐บ AUSTRALIA
๐ธ FINANCIALS
๐งฑ MATERIALS
โณ๏ธ DIVERSIFIED
๐ HIGH PRICE GROWTH
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 8332.1m in AUM and 198 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
๐ Performance (5Yr p.a)
9.85%
๐ Share price
$146.96 AUD
๐ธ FINANCIALS
๐ HIGH PRICE GROWTH
๐ฆ๐บ AUSTRALIA
โณ๏ธ DIVERSIFIED
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
๐ Performance (5Yr p.a)
21.47%
๐ Share price
$54.88 AUD
๐ HIGH PRICE GROWTH
๐บ๐ธ UNITED STATES
๐ค TECHNOLOGY
Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The firm is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimerโs Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamemโs mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamemโs therapeutic potential.
๐ Performance (5Yr p.a)
2.59%
๐ Share price
$0.03 AUD
๐งฌ BIOTECHNOLOGY
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
๐ Performance (5Yr p.a)
11.89%
๐ Share price
$16.28 AUD
๐ GLOBAL
โณ๏ธ DIVERSIFIED
๐ HIGH PRICE GROWTH
๐ค TECHNOLOGY
Want more shares? Try these...